SGHT
Sight Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$8.02
−0.74%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.92
From 52W high−11.38%
Volume453198.00
Market cap$441.81M
P/E (TTM)—
P/S (TTM)5.3x
Div yield—
Key dataSep 18, 2026
Open
$7.92
From 52W high
−11.38%
Volume
453198.00
Market cap
$441.81M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.7x
P/E (TTM)
—
RSI (14)
57.2
MomentumView details →
1D Return
−0.74%
YTD Return
+2.02%
SummaryUpdated Jun 1, 2026
Sight Sciences, Inc. (NASDAQ:SGHT) is a medical device company founded in 2010 and headquartered in Menlo Park, California. The company went public in July 2021 and specializes in developing and commercializing surgical and non-surgical technologies for treating eye diseases. Sight Sciences operates in two primary segments: surgical glaucoma treatment through its <b>OMNI Surgical System</b> and dry eye disease treatment via its <b>TearCare System</b>. The company has faced significant challenges in recent years, including regulatory changes affecting Medicare reimbursement for its glaucoma procedures and ongoing efforts to establish insurance coverage for its dry eye treatments.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration updated the Indications for Use of Sight Sciences' TearCare System to include improvement of meibomian gland function in patients with evaporative dry eye disease, effective August 18, 2026.32d agoSight Sciences, Inc. appointed Kashif Rashid as Chief Legal Officer and Corporate Secretary, effective August 10, 2026, succeeding Jeremy Hayden, who departed from the role.42d ago